Anika Therapeutics, Inc. (ANIK) — SEC Filings
Anika Therapeutics, Inc. (ANIK) — 31 SEC filings. Latest: 10-Q (Nov 5, 2025). Includes 9 8-K, 8 SC 13G/A, 6 10-Q.
View Anika Therapeutics, Inc. on SEC EDGAR
Overview
Anika Therapeutics, Inc. (ANIK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Anika Therapeutics, Inc. (ANIK) reported a net loss of $2.3 million for the three months ended September 30, 2025, a significant improvement from the $29.9 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $11.2 million, compared to $34.5 mil
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 29 neutral, 2 mixed. The dominant filing sentiment for Anika Therapeutics, Inc. is neutral.
Filing Type Overview
Anika Therapeutics, Inc. (ANIK) has filed 6 10-Q, 9 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 1 DEFA14A, 2 SC 13D/A, 1 10-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of ANIK's 26 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $82.2M |
| Net Income | -$11.2M |
| EPS | N/A |
| Debt-to-Equity | 0.16 |
| Cash Position | $58.0M |
| Operating Margin | -14.2% |
| Total Assets | $189.4M |
| Total Debt | $30.0M |
Key Executives
- DarlingMember
- BlanchardMember
- David Johnson
- Dr. Charles L. ("Chip") Wilson
- William Jellison
- Bradley F. Simon
- Douglas Granat
- Lawrence A. Oberman
- Steven G. Simon
- Steven R. Monieson
Industry Context
Anika Therapeutics operates in the competitive medical device sector, specifically focusing on OA Pain Management and Regenerative Solutions. This industry is characterized by rapid technological advancements, significant R&D investment, and stringent regulatory oversight from bodies like the FDA. Companies often pursue strategic divestitures to streamline operations and focus on high-growth areas, as Anika has done.
Top Tags
amendment (7) · corporate-governance (5) · financial-reporting (5) · institutional-ownership (5) · 10-Q (4) · proxy-statement (3) · medical-devices (3) · 8-k (3) · Anika Therapeutics (3) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $2.3M | Significant improvement from $29.9M net loss in Q3 2024 |
| Net Loss (YTD Q3 2025) | $11.2M | Reduced from $34.5M net loss in YTD Q3 2024 |
| Revenue (Q3 2025) | $27.8M | Decrease from $29.6M in Q3 2024 |
| Revenue (YTD Q3 2025) | $82.2M | Decrease from $89.3M in YTD Q3 2024 |
| Income from Discontinued Operations (Q3 2025) | $0.8M | Shift from $28.1M loss in Q3 2024 due to divestitures |
| Cash and Cash Equivalents (Sept 30, 2025) | $58.0M | Increase from $55.6M at Dec 31, 2024 |
| Net Cash from Operating Activities (YTD Q3 2025) | $6.6M | Increased from $3.8M in YTD Q3 2024 |
| Promissory Note from Arthrosurface Sale | $7.0M | Non-interest-bearing note received as consideration |
| Cash from Parcus Medical Sale | $4.5M | Cash consideration received at closing |
| Net Loss (Q2 2025) | $1.5M | Improved from $10.2M net loss in Q2 2024 |
| Revenue (Q2 2025) | $35.0M | Increased 7.7% from $32.5M in Q2 2024 |
| Net Loss (YTD 2025) | $10.0M | Improved from $20.1M net loss in YTD 2024 |
| Revenue (YTD 2025) | $68.0M | Increased 6.3% from $64.0M in YTD 2024 |
| Share Repurchases (YTD 2025) | $2.5M | Used to buy back 100,000 shares |
| R&D Expenses (Q2 2025) | $8.0M | Reflects ongoing investment in product innovation |
Forward-Looking Statements
- {"claim":"Anika Therapeutics' stock price may experience short-term volatility due to Vanguard's reduced stake.","entity":"Anika Therapeutics Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Trigran Investments, Inc. will maintain a significant stake in Anika Therapeutics, Inc. for the foreseeable future.","entity":"Trigran Investments, Inc.","targetDate":"December 31, 2024","confidence":"medium"}
- {"claim":"Anika Therapeutics' stock price will remain relatively stable due to the continued institutional support.","entity":"Anika Therapeutics Inc","targetDate":"Q2 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Anika Therapeutics, Inc. (ANIK)?
Anika Therapeutics, Inc. has 31 recent SEC filings from Jan 2024 to Nov 2025, including 9 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANIK filings?
Across 31 filings, the sentiment breakdown is: 29 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Anika Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anika Therapeutics, Inc. (ANIK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anika Therapeutics, Inc.?
Key financial highlights from Anika Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANIK?
The investment thesis for ANIK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Anika Therapeutics, Inc.?
Key executives identified across Anika Therapeutics, Inc.'s filings include DarlingMember, BlanchardMember, David Johnson, Dr. Charles L. ("Chip") Wilson, William Jellison and 5 others.
What are the main risk factors for Anika Therapeutics, Inc. stock?
Of ANIK's 26 assessed filings, 0 were flagged high-risk, 13 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Anika Therapeutics, Inc.?
Recent forward-looking statements from Anika Therapeutics, Inc. include guidance on {"claim":"Anika Therapeutics' stock price may experience short-term volatility due to Vanguard's reduced stake.","entity and 2 other predictions.